Table 2.
Summary of the effects of chronic treatment with iloperidone and asenapine on the CYP2D protein/activity in the liver and brain.
| Drug | Liver | Brain Structures | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| FCx | St | NA | Hp | Ht | Bs | SN | Cb | RM | ||
| Iloperidone (D2, D3, 5-HT2A, α1, α2) |
|
|
|
|
|
|
|
|
|
|
| Asenapine (D1,D2, D3, D4, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7, α1, α2, H1) |
|
|
|
|
|
|
|
|
|
|
↑, ↓ Increase or decrease, respectively; —no change in the CYP2D activity; receptors mentioned in the brackets display Ki below 20 nM [3]; the effect of asenapine on CYP2D is based on Danek et al., 2021 [47]; FCx—the frontal cortex, St—the striatum, NA—the nucleus accumbens, Hp—the hippocampus, Ht—the hypothalamus, Bs—the brain stem, SN—the substantia nigra, Cb—the cerebellum and RM—the remainder.